UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
June 3, 2015
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-32335 | 88-0488686 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
11388 Sorrento Valley Road, San Diego, California | 92121 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (858) 794-8889
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 5, 2015, Halozyme Therapeutics, Inc. (the Company) announced that Laurie Stelzer had been appointed to serve as the Companys Senior Vice President and Chief Financial Officer effective as of June 15, 2015.
Ms. Stelzer, age 47, has served since 2012 in various finance and investor relations positions at Shire Pharmaceuticals, most recently as Senior Vice President Finance for R & D, Technical Operations and Business Development. From 1997 through 2012, Ms. Stelzer served in various capacities in the finance, treasury, and business development areas at Amgen. Ms. Stelzer received a B.S. in Accounting from Arizona State University and an MBA from UCLA. She is a CPA.
There are no family relationships between Ms. Stelzer and any director, executive officer or person nominated or chosen to become a director. Ms. Stelzer does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.
Ms. Stelzer will be paid an annual salary $420,000 and she will be eligible to participate in the Companys executive officer incentive plans, with a bonus target for her first year equal to 40 % of her prorated base salary. Upon joining the Company, Ms. Stelzer will be granted a stock option for 225,000 shares of common stock and will receive restricted stock units for 27,500 shares. The options and RSUs will vest on the Companys standard four year schedule. The Company will also pay Ms. Stelzer a relocation assistance amount of $150,000 and a sign-on bonus of $50,000 to cover up-front relocation costs.
On June 3, 2015, David A. Ramsay, advised the Company that he would be resigning from his position as Vice President, Chief Financial Officer effective as of June 15, 2015. He will be retiring following assisting in the transition of his responsibilities to Ms. Stelzer.
On June 5, 2015, the Company issued a press release announcing the appointment of Ms. Stelzer as Senior Vice President and Chief Financial Officer and the retirement of Mr. Ramsay, which press release is attached hereto as Exhibit 99.1.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. |
Description | |
99.1 | Press release, dated June 5, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Halozyme Therapeutics, Inc. | ||||||
June 5, 2015 | By: | /s/ Harry J. Leonhardt | ||||
Harry J. Leonhardt | ||||||
Senior Vice President, General Counsel and Chief Compliance Officer |
Exhibit 99.1
Contacts: | ||||
Schond Greenway | ||||
Halozyme Therapeutics | ||||
858-704-8352 | ||||
ir@halozyme.com | ||||
Jim Mazzola | ||||
Halozyme Therapeutics | ||||
858-704-8122 | ||||
ir@halozyme.com |
FOR IMMEDIATE RELEASE
HALOZYME ANNOUNCES PLANS FOR CFO TRANSITION,
NAMES LAURIE STELZER CFO
SAN DIEGO, June 5, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech company, today announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume CFO duties on June 15 and will work with Ramsay through a transition period.
Since last year, David and I have been working closely to plan for his eventual retirement and I am thrilled to now welcome a finance executive of Lauries caliber, said Dr. Helen Torley, president and chief executive officer. David helped guide Halozyme for more than a decade as the company built a significant partner model with our ENHANZE platform and more recently as we laid the foundation for the development of our oncology programs. I want to thank him for the value he has created for our employees and shareholders, and for being a trusted partner to me.
As we prepare for the regulatory submissions and commercialization upon approval of our investigational new drug PEGH20 in the U.S. and Europe, Laurie brings unique experience gained by supporting similar commercial plans at Amgen and Shire.
Most recently at Shire, Stelzer served as senior vice president of Finance for R&D, Technical Operations and Business Development, and was previously Division CFO for Regenerative Medicine. Before Shire, she spent 15 years at Amgen, in senior leadership roles in finance and business development with responsibilities including the U.S., Canada and International Markets, ultimately serving as the companys acting treasurer. In this role, she led a leveraged recapitalization that included $10 billion in bond offerings and the corresponding expanded share buyback program, which contributed to an increase in shareholder value. Stelzer earned her B.S. in Accounting from Arizona State University and MBA from the UCLA Anderson School of Management.
I look forward to joining this growing and dynamic company and helping it achieve the full potential of PEGPH20 and the ENHANZE platform, said Stelzer. I am impressed with the strong management team Helen has assembled and see a great opportunity to make a difference in the effectiveness of cancer therapy.
Earlier this week, Halozyme announced a substantial new global collaboration with drug giant, AbbVie, and presented encouraging interim data on its phase 2 study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer. Halozyme plans to initiate its pivotal phase 3 study of PEGPH20 in the first quarter of 2016.
As a long-term shareholder, I am proud of the progress the company has made and will watch with great confidence as Helen, Laurie and the rest of the team lead the company into the future, said Ramsay.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozymes lead proprietary program, an investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen, Baxter and AbbVie for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information, visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words believe, enable, may, will, could, intends, estimate, anticipate, plan, predict, probable, potential, possible, should, continue, and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected fluctuations or changes in revenues from collaborators, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Companys Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2015.
###
D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#044%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&